Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

11.870
-0.050-0.42%
Volume:3.28M
Turnover:38.38M
Market Cap:11.44B
PE:-36.16
High:12.200
Open:12.200
Low:11.430
Close:11.920
Loading ...

BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China

Reuters
·
04 Jun

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Reuters
·
04 Jun

HK Movers|Pharma Shares Jumped. Innovent Bio Up 15%; Zai Lab Up 5%; Junshi Bio And CSPC Pharma Up 4%

Tiger Newspress
·
04 Jun

Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment

Reuters
·
04 Jun

HK Movers|HK's Pharma Shares Jumped. Medlive Up 8%; Sihuan Pharm And Junshi Bio Up 7%; Pharmaron And Fosun Pharma Up 5%

Tiger Newspress
·
03 Jun

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Reuters
·
30 May

HK Movers | Biopharmaceutical Stocks Jump With SinoMab BioScience up 18%

Tiger Newspress
·
30 May

Ascletis Pharma's Application for Plaque Psoriasis Drug Cleared by US FDA

MT Newswires Live
·
22 May

BRIEF-Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis

Reuters
·
22 May

BRIEF-Ascletis Pharma Says US FDA Cleared IND Application For Oral Small Molecule IL-17 Inhibitor, ASC50

Reuters
·
22 May

Ascletis Pharma Inc. Announces FDA Clearance for Phase I Trial of ASC50, a Promising Oral IL-17 Inhibitor for Psoriasis Treatment

Reuters
·
22 May

Ascletis Pharma Inc. Conducted Annual General Meeting

Reuters
·
22 May

Ascletis Doses First Patients for US Trial of Obesity Drug Combo

MT Newswires Live
·
21 May

HK Movers | HK's Biotech Shares Soar. Asymchem up 15%; Laekna up 13%; Ascletis, CanSinoBIO up 9%

Tiger Newspress
·
21 May

BRIEF-Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity

Reuters
·
20 May

Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment

Reuters
·
20 May

HK Movers | HK's Biotech Shares Soar. Cstone Pharma Soars 20%; RemeGen up 10%; Ascletis up 6%

Tiger Newspress
·
20 May

HK Movers | HK's Biotech Shares Pull Back. Alphamab, Cstone Pharma, Ascletis down about 10%; Immuneonco, Laekna down over 9%

Tiger Newspress
·
12 May

Ascletis Pharma to Present Results of Preliminary Studies on Anti-Obesity Drug

MT Newswires Live
·
06 May

Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results

MT Newswires Live
·
23 Apr